Tape preparation of WT1 peptide cancer vaccine for transdermal administration
The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.
1. A method for inducing cellular immunity in a subject, which comprises applying a cancer vaccine tape preparation, comprising:
a support, and
an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) imiquimod;
(iii) at least one helper peptide and/or modified helper peptide; and
(iv) myristic acid,
to the skin of the subject under a mildly irritating condition.
2. The method according to claim 1 , wherein the method is for treating a cancer in the subject.
3. The method according to claim 1 , wherein the adhesive of the tape preparation is an acrylic adhesive.
4. The method according to claim 1 , wherein the adhesive of the tape preparation is a rubber-based adhesive.
5. The method according to claim 4 , wherein the rubber-based adhesive is polyisobutylene rubber adhesive.
6. The method according to claim 1 , wherein the adhesive of the tape preparation is a silicone-based adhesive.
7. The method according to claim 1 , wherein the adhesive layer further carries a skin permeability enhancer.
8. The method according to claim 1 , wherein the mildly irritating condition is a condition under which transepidermal water loss (TEWL) in a model animal for skin irritation evaluation before the administration of the composition is 50 g/h·m 2 or less.
9. The method according to claim 1 , wherein the mildly irritating condition is a condition under which the cutaneous TSLP level in a model animal for skin irritation evaluation at completion of the administration of the composition is 10000 pg/mg protein or less.
10. The method according to claim 1 , wherein the helper peptide is at least tubercle bacillus-derived helper peptide, measles virus-derived helper peptide, hepatitis B virus-derived helper peptide, hepatitis C virus-derived helper peptide, Chlamydia trachomatis -derived helper peptide, Plasmodium falciparum sporozoite-derived helper peptide, keyhole limpet haemocyanin-derived helper peptide, tetanus toxin-derived helper peptide, universal helper analog or cancer cell-derived helper peptide, excepting a WT1-derived helper peptide.
11. The method according to claim 1 , wherein the cancer vaccine tape preparation also comprises a cyclooxygenase inhibitor.
12. The method according to claim 1 , wherein the helper peptide is hWT1 35 helper peptide, hWT1 86 helper peptide, or hWT1 294 helper peptide.
13. A cancer vaccine tape preparation for use in the induction of cellular immunity, comprising:
a support, and
an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) imiquimod;
(iii) at least one helper peptide and/or modified helper peptide; and
(iv) myristic acid,
wherein the tape preparation is structurally configured and arranged for application to the skin of a subject.
14. The cancer vaccine tape preparation for use in the induction of cellular immunity according to claim 13 , wherein the helper peptide is at least tubercle bacillus-derived helper peptide, measles virus-derived helper peptide, hepatitis B virus-derived helper peptide, hepatitis C virus-derived helper peptide, Chlamydia trachomatis -derived helper peptide, Plasmodium falciparum sporozoite-derived helper peptide, keyhole limpet haemocyanin-derived helper peptide, tetanus toxin-derived helper peptide, universal helper analog or cancer cell-derived helper peptide, excepting a WT1-derived helper peptide.
15. The cancer vaccine tape preparation for use in the induction of cellular immunity according to claim 13 , wherein the adhesive layer also carries a cyclooxygenase inhibitor.